New Research Report of Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma
ResearchMoz added Latest Research Report titled " Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma " to it's Large Report database.
Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended for aggressive disease. Across both indolent and aggressive disease, first-line chemotherapy in combination with the blockbuster drug rituxumab can induce high rates of response, and prolonged durations of remission.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=373016
Despite this, indolent disease is typically incurable, with the most aggressive lymphoma subtype - diffuse large B-cell lymphoma having 5-year survival rates of ~50%. Re-treatment with chemotherapy can induce second and subsequent remissions, but most NHL patients develop chemotherapy resistant disease, for whom there are limited treatment options. Overall, in terms of numbers small molecule chemotherapeutic agents dominate the current market, with a clear need for novel targeted therapies to prolong durations of remission, and provide options for patients with chemo resistant, heavily pretreated disease.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Development of Targeted Therapies Remains a Focus across NHL Drug Development
2.2 NHL Shows a Moderate Level of First-in-Class Innovation
2.3 High Number of First-in-Class Pipeline Drugs with No Associated Deal
3 The Case for Innovation in NHL Development
3.1 Growing Opportunities for Biological Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance
4 Clinical Landscape
4.1 Disease Overview
4.2 Epidemiology and Risk Factors
4.3 Symptoms
4.4 Diagnosis
4.4.1 Biopsy
4.4.2 Flow-Cytometry and Immunophenotyping
4.5 Normal B-Cell Development and NHL Classification
4.6 Pathophysiology
4.6.1 BCL-2
4.6.2 BCL-6
4.6.3 Wnt/ß-catenin Pathway
4.6.4 BCR Pathway
4.6.5 PI3K/Akt/mTOR Pathway
4.7 Patient Prognosis
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended for aggressive disease. Across both indolent and aggressive disease, first-line chemotherapy in combination with the blockbuster drug rituxumab can induce high rates of response, and prolonged durations of remission.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=373016
Despite this, indolent disease is typically incurable, with the most aggressive lymphoma subtype - diffuse large B-cell lymphoma having 5-year survival rates of ~50%. Re-treatment with chemotherapy can induce second and subsequent remissions, but most NHL patients develop chemotherapy resistant disease, for whom there are limited treatment options. Overall, in terms of numbers small molecule chemotherapeutic agents dominate the current market, with a clear need for novel targeted therapies to prolong durations of remission, and provide options for patients with chemo resistant, heavily pretreated disease.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Development of Targeted Therapies Remains a Focus across NHL Drug Development
2.2 NHL Shows a Moderate Level of First-in-Class Innovation
2.3 High Number of First-in-Class Pipeline Drugs with No Associated Deal
3 The Case for Innovation in NHL Development
3.1 Growing Opportunities for Biological Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance
4 Clinical Landscape
4.1 Disease Overview
4.2 Epidemiology and Risk Factors
4.3 Symptoms
4.4 Diagnosis
4.4.1 Biopsy
4.4.2 Flow-Cytometry and Immunophenotyping
4.5 Normal B-Cell Development and NHL Classification
4.6 Pathophysiology
4.6.1 BCL-2
4.6.2 BCL-6
4.6.3 Wnt/ß-catenin Pathway
4.6.4 BCR Pathway
4.6.5 PI3K/Akt/mTOR Pathway
4.7 Patient Prognosis
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
New Research Report of Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma
![New Research Report of Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma]()
Reviewed by Sagar Jagtap
on
02:09
Rating:
No comments: